EGFR and non-small cell lung carcinoma: In conclusion, to our knowledge, the current study is the first study to show that maintenance pemetrexed post pemetrexed-carboplatin chemotherapy fails to improve QOL or time to event outcomes (OS and PFS) over maintenance erlotinib in EGFR mutation negative NSCLC.